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Purpose: Although mutated G11778A NADH ubiquinone oxidoreductase subunit 4 (ND4) mitochondrial DNA (mtDNA)
is firmly linked to the blindness of Leber hereditary optic neuropathy (LHON), a bona fide animal model system with
mutated mtDNA complex I subunits that would enable probing the pathogenesis of optic neuropathy and testing potential
avenues for therapy has yet to be developed.
Methods: The mutant human ND4 gene with a guanine to adenine transition at position 11778 with an attached FLAG
epitope under control of the mitochondrial heavy strand promoter (HSP) was inserted into a modified self-complementary
(sc) adeno-associated virus (AAV) backbone. The HSP-ND4FLAG was directed toward the mitochondria by adding the
23 amino acid cytochrome oxidase subunit 8 (COX8) presequence fused in frame to the N-terminus of green fluorescent
protein (GFP) into the AAV2 capsid open reading frame. The packaged scAAV-HSP mutant ND4 was injected into the
vitreous cavity of normal mice (OD). Contralateral eyes received scAAV-GFP (OS). Translocation and integration of
mutant human ND4 in mouse mitochondria were assessed with PCR, reverse transcription–polymerase chain reaction
(RT–PCR), sequencing, immunoblotting, and immunohistochemistry. Visual function was monitored with serial pattern
electroretinography (PERG) and in vivo structure with spectral domain optical coherence tomography (OCT). Animals
were euthanized at 1 year and processed for light and transmission electron microscopy.
Results: The PCR products of the mitochondrial and nuclear DNA extracted from infected retinas and optic nerves gave
the expected 500 base pair bands. RT–PCR confirmed transcription of the mutant human ND4 DNA in mice. DNA
sequencing confirmed that the PCR and RT–PCR products were mutant human ND4 (OD only). Immunoblotting revealed
the expression of mutant ND4FLAG (OD only). Pattern electroretinograms showed a significant decrement in retinal
ganglion cell function OD relative to OS at 1 month and 6 months after AAV injections. Spectral domain optical coherence
tomography showed optic disc edema starting at 1 month post injection followed by optic nerve head atrophy with marked
thinning of the inner retina at 1 year. Histopathology of optic nerve cross sections revealed reductions in the optic nerve
diameters of OD versus OS where transmission electron microscopy revealed significant loss of optic nerve axons in
mutant ND4 injected eyes where some remaining axons were still in various stages of irreversible degeneration with
electron dense aggregation. Electron lucent mitochondria accumulated in swollen axons where fusion of mitochondria
was also evident.
Conclusions: Due to the UGA codon at amino acid 16, mutant G11778A ND4 was translated only in the mitochondria
where its expression led to significant loss of visual function, loss of retinal ganglion cells, and optic nerve degeneration
recapitulating the hallmarks of human LHON.
Leber  hereditary  optic  neuropathy  (LHON)  is  a
maternally inherited disorder that usually results in loss of
vision during the second and third decades of life. The guanine
to adenine transition at nucleotide 11778 in mitochondrial
DNA  (mtDNA)  in  the  gene  specifying  the  nicotinamide-
adenine  dinucleotide  (NADH)  dehydrogenase  subunit  4
(ND4) of complex I causes half the cases [1]. This mutation
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results in an arginine to histidine substitution at amino acid
340 [2]. Of all diseases caused by mutated mitochondria,
LHON is the most common [3]. Complex I contains seven
subunits encoded by mtDNA that are synthesized within the
organelle and 35 subunits encoded by nuclear DNA that are
imported from the cytoplasm [4]. Mutations in two additional
mtDNA encoded complex I subunits, ND1 and ND6, have also
been associated with LHON. Together with ND4, they are
responsible for most of the cases of LHON [5,6]. The ND4
mutation is the most severe, showing little propensity for
spontaneous recovery of vision, thus making this mutation an
attractive target for intervention.
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1668Common  to  most  mitochondrial  encoded  proteins,
mitochondrial ND4 can be translated only in the mitochondria
and not on cytoplasmic ribosomes, because the TGA codon at
positions  16  and  24  that  code  for  tryptophan  in  the
mitochondria are stop codons in the nuclear genetic code.
Since there was no way to introduce DNA directly into the
mitochondria of a live animal, we had previously knocked
down  expression  of  a  critical  nuclear-encoded  complex  I
subunit, NADH ubiquinone oxidoreductase subunit NDUFA1
(NDUFA1), to induce optic neuropathy in the mouse [7].
Several  years  later,  we  added  a  mitochondrial  targeting
sequence  (MTS)  to  the  N-terminus  of  a  nuclear-encoded
version of the mutant human ND4 subunit gene that induced
a phenotype in the mouse with remarkable similarity to the
human LHON disorder [8].
In  this  report,  we  describe  redirection  of  the  adeno-
associated virus (AAV) virion to mitochondria by adding an
MTS to the viral outer capsid to deliver the mutant G11778A
human ND4 gene in the mitochondrial genetic code to the
visual system of mice where the mutant ND4 allele induced
retinal ganglion cell (RGC) dysfunction and optic atrophy.
AAV is a single-stranded DNA parvovirus with a 4.7 kb
genome and a particle diameter of 21 nm. The AAV genome
consists of two genes, replicase (REP) and capsid (CAP),
which  encode  the  non-structural  REP  proteins  (REP78,
REP68, REP52, and REP40) and the capsid proteins (VP1,
VP2, and VP3), respectively. Flanking these two genes are the
inverted terminal repeat (ITR) sequences that provide all the
cis-acting sequences required for replication, packaging, and
integration [9]. The VP2 capsid protein of AAV serotype 2
can tolerate large peptide insertions at the N-terminus without
loss of infectivity [10]. However, VP2 is not essential for the
infectivity of AAV, and in the AAV capsid only three of 60
subunits are VP2.
METHODS
Plasmids:  To  construct  the  fusion  gene  containing  the
mitochondrial promoter, human wild-type ND4 and epitope
tag, mitochondrial DNA was extracted from human cells.
Using  the  high  fidelity  of  pfu  Turbo  DNA  polymerase
(Stratagene,  Santa  Clara,  CA),  the  1.4  kb  mitochondrial
encoded ND4 gene was cloned into the Topo TA cloning
vector using a kit according to the manufacturer's directions
(Invitrogen, Carlsbad, CA). A final extension step using Taq
DNA polymerase was also performed. The QuikChange in
vitro mutagenesis kit (Stratagene) was used to add the FLAG
epitope tag with appended AGA termination codon to the 3′
end of the open reading frame of the ND4 gene to obtain
ND4FLAG. Base deletions and substitutions in the reading
frame ND4FLAG were corrected using the QuikChange in
vitro mutagenesis kit (Stratagene). Human wild-type ND4
fused in frame with FLAG was cloned into pCDNA3 and used
as  a  template  to  generate  mutant  human  ND4  with  a
substitution of A for G at nucleotide 1019 with site-directed
mutagenesis (Quikchange II XL site-directed mutagenesis kit;
Stratagene).  After  confirmation  with  sequencing,  the
generated mutant ND4G1019AFLAG was then cloned into
self-complementary AAV backbones under the control of the
mitochondrial heavy strand promoter (HSP). The parent pTR-
UF plasmid was digested with Xba I and BamHI to remove
the green fluorescent protein (GFP) and neomycin resistance
(neoR) genes. The Topo plasmid containing the mitochondrial
ND4FLAG  was  also  digested  with  Xba  I  and  BamHI  for
directional cloning into the similarly digested recipient pTR-
UF11 plasmid. The ND4FLAG insert was then ligated into the
recipient pTR-UF11 plasmid. This gave the desired plasmid
designated  as  pTR-UF11-mND4FLAG.  Next,  the  hybrid
CMV enhancer and chicken β-actin promoter elements (used
to drive gene expression in the nucleus) was removed from
pTR-UF11-ND4FLAG using KpnI and Xba I digests. We
purchased  complementary  oligonucleotides  (Invitrogen)
containing the mitochondrial HSP, sequence 5′-TAA CCC
CAT ACC CCG AAC CAA CCA AAC CCC AAA GAC
AC-3′ with added linkers containing the KpnI restriction site
at the 5′ end and Xba I at the 3′ end of HSP. The annealed
double-stranded  HSP  oligonucleotide  was  directionally
ligated into the pTR-UF11-ND4FLAG to give plasmid pTR-
UF11-HSP-ND4FLAG. We then inserted HSP-ND4FLAG or
HSP mutantND4FLAG into a self-complementary (sc) AAV
backbone. The parent SC-trs-SB-smCBA-hGFP plasmid was
digested with KpnI and BamHI to remove the hybrid CMV
enhancer and small chicken β-actin promoter elements as well
as GFP. The insert containing HSP-ND4FLAG was digested
out of pTR-UF11-HSP-ND4FLAG using restriction enzymes
KpnI and Xba I, and was then ligated into the recipient scAAV
backbone  generating  the  construct  sc-HSP-ND4FLAG
containing  flanking  ITRs  that  provide  all  the  cis-acting
sequence required for replicating, packaging, and integrating
the AAV vector.
To generate an AAV directed toward the mitochondria,
we added a mitochondrial targeting sequence (MTS) to the
open reading frame of VP2, one of the three capsid proteins
that constitute an AAV virion. This MTS-targeted VP2 was
generated by linking the 23 amino acid MTS presequence of
COX8, 5′ATG TCC GTC CTG ACG CCG CTG CTG CTG
CGG GGC TTG ACA GGC TCG GCC CGG CGG CTC CCA
GTG CCG CGC GCC AA- 3′ in frame to GFP. Eag I linkers
were added to the COX8GFP insert. The parent VP2 plasmid
with an Eag I site inserted at residue 138 within the VP1-VP2
overlap region was digested with Eag I. The COX8GFP was
ligated into the mutant VP2 parent plasmid. This created the
plasmid  designated  COX8GFP  VP2.  Construction  of  the
mutant  VP2  parent  plasmid  and  the  GFP-containing  VP2
mutant  plasmid  without  the  MTS  has  previously  been
described [10].
Adeno-associated  viruses:  Self-complementary  AAV2/sc-
HSP-ND4FLAG,  HSP  mutantND4FLAG  or  a  control
scAAV2-GFP was produced with the plasmid cotransfection
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1669method  [11].  The  plasmids  were  packaged  with  the
COX8GFP VP2 (mutant or wild-type human ND4) using the
PXX6  helper  plasmid  (threefold  excess)  into  the  AAV2
recombinant virus by transfection into human 293 cells with
standard procedures. Briefly, the crude iodixanol fractions
were purified using the Pharmacia AKTA FPLC system, the
virus was then eluted from the column with 215 mM NaCl,
pH 8.0, and the rAAV peak was collected. rAAV-containing
fractions were then concentrated and buffer exchanged in
Alcon BSS with 0.014% Tween-20, with a Biomax 100 K
concentrator (Millipore, Billerica, MA). The virus titer was
then measured for DNase-resistant viral genomes with real-
time PCR relative to a standard. Finally, the purity of the virus
was validated with silver-stained sodium dodecyl sulfate–
PAGE, assayed for sterility and lack of endotoxin, and then
aliquoted and stored at −80 °C.
Cell culture and infection: Human embryonal kidney cells
(293T) or mouse embryonal fibroblasts infected with AAV
vectors  were  cultured  in  complete  high-glucose  medium
(DMEM). The endogenous fluorescence of COX8GFP VP2
scAAV-infected cells was observed in live cells. The cells
cultured  on  plastic  chamber  slides  were  reacted  with
MitoTracker  Green  according  to  the  manufacturer's
specifications  (Invitrogen)  and  then  fixed  in  4%
paraformaldehyde  for  examination  with  a  confocal
microscope.
Animals:  All  animal  procedures  were  performed  in
accordance with the National Institutes of Health Guide for
Care  and  Use  of  Laboratory  Animals  and  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research  and  approved  by  the  UM  IACUC.  For  the
intraocular injection of recombinant AAV, DBA/1J mice were
sedated by inhalation with 1.5% to 2% isoflurane. A local
anesthetic (proparacaine HCl) was applied topically to the
cornea, and then a 32-gauge needle attached to a Hamilton
syringe was inserted through the pars plana. One microliter of
MTS-targeted  scAAV2  containing  mutant  or  wild-type
human ND4 DNA (1.01×1011 VG/ml), 2.19×1012 VG/ml) was
injected in the right eye and scAAV-GFP (1.03×1012 VG/ml)
injected into the left eye. The animals were euthanized at
certain time points post injection.
Electrophysiology:  In  brief,  mice  were  weighed  and
anesthetized with intraperitoneal injections of a mixture of
ketamine (80 mg/kg bodyweight) and xylazine (10 mg/kg
bodyweight) and were restrained with a bite bar and a nose
holder that allowed unobstructed vision. The animals were
kept  at  a  constant  body  temperature  of  37.6  °C  with  a
feedback-controlled heating pad. In these conditions, the eyes
were wide open and in a stable position with undilated pupils
pointing  laterally  and  upward.  The  electroretinogram
electrode had a diameter of 0.25 mm, and was made of silver
wire configured to a semicircular loop with a 2-mm radius,
which  was  placed  on  the  corneal  surface  with  a
micromanipulator and positioned to encircle the pupil without
limiting the field of view. Reference and ground electrodes
were stainless-steel needles inserted under the skin of the scalp
and tail, respectively. After the mice were set on the stage and
before responses were recorded, a small drop of balanced
saline was topically applied on the cornea to prevent drying.
A  visual  stimulus  of  contrast-reversing  bars  (field  area,
50°×58°; mean luminance, 50 cd/m2; spatial frequency, 0.05
cycles/deg; contrast, 100%; and temporal frequency, 1 Hz)
was aligned with the projection of the pupil at a distance of
20 cm. The eyes were not refracted for the viewing distance,
because the mouse eye has a large depth of focus due to the
pinhole pupil. Retinal signals were amplified (10,000 fold)
and  band-pass  filtered  (1–30  Hz).  Three  consecutive
responses to 600 contrast reversals each were recorded. The
responses were superimposed to check for consistency and
then averaged. Pattern electroretinography (PERG) is a light-
adapted response. To have a corresponding index of outer
retinal function, light-adapted flash electroretinography was
also  recorded  with  undilated  pupils  in  response  to  strobe
flashes of 20 cd/m2/s superimposed on a steady background
light of 12 cd/m2 and presented within a Ganzfeld bowl. Under
these conditions, rod activity is largely suppressed while cone
activity is minimally suppressed. To prevent bias in evaluating
the peaks and troughs of PERG waveforms with reduced
amplitude, the root-mean-square (RMS) voltage of the PERG
signal was calculated. Response amplitude was defined as the
RMS voltage over a time epoch of 0 to 350 ms after each
contrast reversal according to the equation [VRMS=√ ((Σ
vi
2)/n], where VRMS is the amplitude, vi
2 is the voltage at each
sampled time point, and n is the number of sampled points.
RMS evaluation was automatically performed using a macro
written  in  Sigma  Plot  language  (Sigmaplot  11.2,  Systat
Software Inc., San Jose, CA).
In vivo imaging: In vivo high-resolution imaging of the living
mouse retina was performed with spectral domain optical
coherence tomography (OCT), as previously described [12].
Briefly, ketamine/xylazine anesthetized mice were restrained
in a mounting tube that was fixed on a platform. Rasterscans
—typically measuring 512×128 (horizontal x vertical) and
1024×64  depth  scan  patterns,  with  the  fast  scan  in  the
horizontal direction—were performed for each eye. The scan
length was approximately 32° for imaging mouse retinas.
Acquiring high-quality OCT images took approximately 5
min for each mouse.
Polymerase  chain  reaction  and  reverse  transcriptase–
polymerase  chain  reaction:  Mitochondrial  and  nuclear
fractions were isolated from pooled ocular tissues (n=6 mice).
DNA and RNA were extracted respectively from each fraction
with  the  DNeasy  Blood  and  Tissue  Kit  (Qiagen)  and  the
RNeasy Protect Mini Kit (Qiagen). Reverse transcription was
performed with the IScript One-Step RT–PCR kit (Bio-Rad).
PCR was performed using primers hND4F1: 5′-ATG CTA
AAA CTA ATC GTC C-3′ and hND4R1403: 5′-CTC TTG
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1670TCA TCG TCG TCC-3′ for full-length ND4FLAG of 1.4 kb;
hND4F5415: 5′-TGC ATA CTC TTC AAT CAG CC-3′ and
hND4R1403: 5′-CTC TTG TCA TCG TCG TCC-3′ for 500
bp ND4FLAG. The resultant PCR products were sequenced
with primer hND4F5415: 5′-TGC ATA CTC TTC AAT CAG
CC-3′ or hND4F1: 5′-ATG CTA AAA CTA ATC GTC C-3′.
Histology and ultrastructure: At the appropriate time points,
all mice inoculated with the AAV vectors were injected with
Euthasol  Solution.  They  were  then  perfused  by  cardiac
puncture with phosphate buffered solution (PBS; Na2HPO4
10.9 g, NaH2PO4 3.2 g, NaCl 90 g, H2O 1000 ml; pH to 7.4)
and then with fixative consisting of 4% paraformaldehyde in
0.1 M PBS buffer (pH 7.4). Whole retinas or longitudinal
retinal  sections  were  used  for  immunofluorescence.  The
following  antibodies  were  used:  Cy3-conjugated  FLAG
(1:100;  Sigma),  porin  (1:100;  Abcam),  Thy1.2  (1:1500;
Sigma), GFP (1:100; Sigma), NADH dehydrogenase subunit
4 (1:480; Abcam), and secondary antibodies that included
antirat 488, antimouse Cy5, antirabbit 647, antirabbit Cy3
(1:600;  Invitrogen),  or  antimouse  immunoglobulin
conjugated to immunogold (Ted Pella, Redding, CA) that was
enhanced  with  a  kit  according  to  the  manufacturer’s
specifications  (Ted  Pella).  Images  were  visualized  with  a
Leica TCS (Buffalo Grove, IL) SP5 confocal microscope.
For electron microscopy, infected cultured cells or the
eyes and optic nerves of infected rodents that were dissected
after  euthanasia  and  perfusion  with  fixative  (4%
paraformaldehyde,  2.5%  glutaraldehyde)  were  further
processed  by  immersion  fixation  in  2.5%  glutaraldehyde,
postfixed in 1% osmium tetroxide, 0.1 M sodium cacodylate-
HCl buffer (pH 7.4), and 7% sucrose in the cold, and then
dehydrated  through  an  ethanol  series  to  propylene  oxide,
infiltrated, and embedded in epoxy resin that was polymerized
at  60  °C  overnight.  For  immunocytochemistry,  tissue
specimens were postfixed in 5.0% acrolein, 0.1 M sodium
cacodylate-HCl buffer (pH 7.4), and 7% sucrose and then
dehydrated through an ethanol series and embedded in LR
White (Ted Pella) that was polymerized at 50 °C overnight.
Semithin longitudinal sections (0.5 µm) of the optic nerve
head and retrobulbar nerve were stained with toluidine blue
for light microscopic examination. Ultrathin sections (90 nm)
were placed on nickel grids for immunocytochemistry with
anti-FLAG antibodies or GFP antibodies counterstained by
secondary antibodies conjugated to 5-nm immunogold. The
gold particles were then amplified with a silver enhancement
kit  (Ted  Pella).  Examinations  were  made  with  a  Hitachi
H-7600  (Tokyo,  Japan)  with  a  tilting  stage  for  three-
dimensional rendering of the collected images or an H-7650
transmission electron microscope, operating at 200 or 80 kV,
respectively.
Immunoblotting: For western blot analysis, sonicated proteins
from total cellular lysates or mitochondrial pellets obtained
from  infected  ocular  tissues  (n=10  mice)  were
electrophoresed  through  a  10%  polyacrylamide  gel  and
electrotransferred  to  a  polyvinylidene  fluoride  membrane.
The membrane was immunostained with antibodies against
ND4 (1:200; Santa Cruz, Santa Cruz, CA), FLAG (1:2,000;
Sigma), or NDUFS4 (1:1,000; Mitosciences, Eugene, OR)
followed  by  either  antimouse  or  antirabbit  horseradish
peroxidase (HRP)-conjugated antibodies. Immune complexes
were  detected  using  ECL  reagents  (HRP-conjugated
antibodies) and a FUJIFilm Imaging system (Valhalla, NY).
Optic nerve areas and axon counts: One year after the viral
gene injections, the optic nerves were dissected from 1 mm
behind the globe to the optic chiasm. After the specimens were
prepared, toluidine blue stained images were collected using
an Olympus IX50 microscope, equipped with an Olympus
DP7e CCD camera (Olympus America, Melville, NY). The
optic  nerve  cross  sections  were  manually  traced  for  area
measurements by an observer masked to the treatment. For
the axon counts, 15 transmission electron micrographs were
photographed at low magnification (2,500×) for each mutant
ND4 injected optic nerve specimen and five micrographs for
controls injected with AAV-GFP. The number of axons was
then manually counted by an observer masked to the treatment
agent. Axons were identified by the internalized neurotubules
and  axolemma  surrounded  by  the  electron-dense  myelin
sheath. Axons counts were expressed per mm2.
Statistical  analysis:  Values  were  expressed  as  means
±standard deviation (SD). Data were analyzed via the Student
t-test  for  paired  data.  p  values  of  <0.05  were  considered
significant, and p<0.01 was highly significant.
RESULTS
Mitochondrial targeting sequence modified AAV does not lose
infectivity:  We  directed  the  AAV  virion  toward  the
mitochondria  by  adding  the  23  amino  acid  cytochrome
oxidase subunit 8 (COX8) presequence fused in frame to the
N-terminus of GFP into the AAV2 capsid open reading frame
(Figure 1A). To direct expression of exogenous wild-type
human  ND4  in  the  organelle,  we  linked  a  mitochondrial
promoter, the HSP, to the N-terminus of either wild-type
human ND4 or G11778A ND4 cDNA (Figure 1B) to a scAAV
backbone  that  contained  AAV2  inverted  terminal  repeats
(ITRs). For immunodetection, we linked a FLAG epitope to
the C-terminus of G11778A ND4. The COX8 GFP coding
sequence was ligated into the AAV capsid VP2 gene at a
unique  EAGI  site  at  residue  138.  This  insertion  did  not
substantially  reduce  infectivity  of  the  recombinant  AAV
[13], as we achieved relatively high titers (2.2×1012 vg/ml) for
this mitochondria-targeted AAV.
Mitochondrial  targeting  sequence  AAV-capsid  localizes
within  mitochondria  where  the  delivered  human  ND4  is
translated in cultured cells: Fluorescence microscopy of live
cultured cells infected with the COX8GFP VP2 MTS AAV
revealed punctate and perinuclear expression of GFP (Figure
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16711C), suggestive of mitochondrial localization. Cells stained
with a bona fide mitochondrial marker MitoTracker Green
revealed  a  similar  cellular  distribution  of  mitochondria
(Figure 1D). To determine if the MTS AAV virion entered the
mitochondria,  we  used  transmission  electron  microscopy
where GFP labeled by silver enhanced immunogold decorated
Figure 1. MTS AAV-capsid localizes within mitochondria where the delivered wild-type human ND4 is translated in cultured cells. A:
Illustration of the COX8 MTS fused in frame with GFP and inserted into the VP2 capsid of AAV. B: Illustration of the mitochondrial heavy
strand promoter (HSP) driving expression of the mitochondrial mutant human ND4 subunit of complex I to which is appended a FLAG epitope.
C: Fluorescence microscopy of live cultured cells infected with the COX8GFP VP2 MTS AAV revealed punctate and perinuclear expression
of GFP suggestive of mitochondrial localization. D: MitoTracker Green staining of mitochondria surrounds nuclei labeled with DAPI. E:
Transmission electron microscopy shows silver enhanced GFP immunogold inside mitochondria as well as within the nucleus. F: ND4FLAG
immunogold is evident only within the mitochondria. Abbreviations m=mitochondria and n=nucleus.
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1672Figure 2. Mutant human G11778A ND4 transmission in mice. A: RT–PCR of RNA extracted from retinal mitochondria (RM), optic nerve
mitochondria (OM), retinal nuclear (RN), or optic nerve nuclear (ON) debris, retinal cytoplasm (RC), and optic nerve cytoplasmic (OC)
fractions of experimental right eyes had the expected 500 bp band for ND4FLAG that was absent in RNA extracted from control left eyes
infected with scAAV-GFP. B: A sequencing chromatograph shows the corresponding DNA sequence to be that of the mutant human ND4
where the base adenine (A; arrows) has replaced guanine (G). C: One of the sequences, SEQmutND41-OM, is aligned to the wild-type human
ND4 (ND4mito) showing this G to A transition (arrows). It also reveals the sequence of the mouse ND4 (mitoND4mouse) confirmed that the
PCR products were indeed mutant human G11778A ND4, further supporting that exogenous ND4 was imported into retinal and optic nerve
mitochondria by a mitochondria-targeted AAV where it was transcribed. D: Immunoblotting of isolated optic nerve and retinal mitochondria
showed that the MTS-targeted AAV directed the synthesis of mutant human ND4FLAG in the experimental eyes, but the control eyes injected
with GFP were negative for FLAG. ND4 was overexpressed in experimental eyes relative to the endogenous ND4 of GFP injected control
eyes. Expression of NDUFS4, a nuclear encoded complex I subunit, is shown for housekeeping. E: Amino acid sequence of ND4 with the
start methionine (met) shows that the TGA codon is a termination sequence for protein synthesis in the cytoplasm, but specifies the amino
acid tryptophan for synthesis within the mitochondrial ribosomes. F: Illustrating that full-length ND4 with 340 amino acids can be expressed
only within mitochondria.
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1673the interior of the organelle (Figure 1E). GFP immunogold
was also seen within the nucleus where the AAV typically
delivers  its  DNA.  Control  cells  labeled  only  with  the
secondary antibody showed a background of approximately
one to two gold particles per micrograph. In addition, wild-
type ND4FLAG labeled by immunogold was seen only within
the organelle (Figure 1F). Thus, it appears that, at least in
cultured cells, a mitochondrial-encoded gene can be delivered
to the interior of the organelle where the protein specified by
the gene is translated.
Mutant human G11778A ND4 transmission in mice: Next, we
tested for MTS AAV DNA in the mouse visual system. Here
the right eyes of the mice received injections into the vitreous
body  of  sc-HSP-ND4FLAG  or  sc-HSP  mutantND4FLAG
packaged by COX8GFP VP2 AAV. Injections of scAAV-
GFP into the left eyes served as controls. To determine if the
mitochondria-associated  virus  transferred  mutant  human
ND4FLAG DNA, mitochondrial-enriched, cytoplasmic, and
nuclear DNA fractions were extracted from the retinas and
optic nerves of mice a week after intraocular viral injections.
PCR for ND4FLAG gave the expected 500 kb band for the
retinas  and  optic  nerves  of  COX8  targeted  G11778A
ND4FLAG.  The  corresponding  DNA  sequences  and
alignment to wild-type human and mouse ND4 confirmed that
the  PCR  products  were  indeed  mutant  human  G11778A
ND4, further supporting that exogenous ND4 was imported
into retinal and optic nerve mitochondria by a mitochondria-
targeted AAV.
Mutant  human  G11778A  ND4  transcription  in  mice:  To
determine  if  the  mitochondria-associated  virus  transfer  of
mutant  human  ND4FLAG  DNA  to  the  organelle  was
transcribed,  mitochondrial-enriched,  cytoplasmic,  and
nuclear RNA fractions were extracted from the retinas and
optic nerves of mice a week after intraocular viral injections.
RT–PCR for ND4FLAG gave the expected 500 kb band for
the  retinas  and  optic  nerves  of  MTS-targeted  G11778A
ND4FLAG  (Figure  2A).  DNase  I–treated  control  samples
gave  no  RT–PCR  product.  The  corresponding  DNA
sequences (Figure 2B) and alignment to wild-type human and
mouse ND4 confirmed that the RT–PCR products were indeed
mutant human G11778A ND4 (Figure 2C), supporting that
exogenous  ND4  was  translated  in  retinal  and  optic  nerve
mitochondria  following  gene  delivery  by  a  mitochondria-
targeted AAV.
Mutant  human  G11778A  ND4  translation  in  mice:
Immunoblotting  of  isolated  optic  nerve  and  retinal
mitochondrial proteins showed that the MTS-targeted AAV
directed the synthesis of mutant human ND4FLAG detected
with an anti-FLAG antibody in experimental eyes but not in
control  eyes  injected  with  scAAV-GFP  (Figure  2D).  In
mutant ND4 injected eyes, ND4 (52 kDa) was overexpressed
relative  to  the  control  eyes  injected  with  GFP.  The
housekeeping  NDUFS4  (18  kDa)  protein  is  shown  for
comparison. Although ND4 cDNA and RNA were detected in
Figure 3. Wild-type human ND4 expression in RGCs does not cause
visual  loss  in  mice.  Confocal  immunofluorescence  micrographs
show DAPI stained nuclear layers of the murine retina infected 7
weeks earlier with MTS scAAV containing wild-type normal human
ND4FLAG (A). The RGC layer and dendrites extending into the
inner  nuclear  layer  (INL)  are  labeled  with  an  antibody  against
Thy1.2. The outer nuclear layer (ONL) is not stained by Thy1.2
(B). RGCs expressing human ND4FLAG are labeled by an anti-
FLAG antibody (C) that colocalizes to Thy1.2 and has a perinuclear
distribution characteristic of mitochondria surrounding the DAPI-
stained RGC nuclei (D). A scatterplot (E) and a plot of representative
PERG waveform (F) show that 7 weeks after AAV injections there
were no differences in amplitude between the eyes injected with
wild-type human mitochondrial (m) ND4 relative to the eyes that
received no ocular gene injections.
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1674the nucleus and cytoplasm, translation of ND4 can occur only
Figure 4. Mutant human ND4 expression induces visual loss in mice.
A: At 1 month post injection, a scatterplot of a root-mean-square
(RMS) PERG amplitude shows a significant loss of visual function
of the right eyes injected with the mutant human ND4 packaged with
the MTS scAAV relative to the left eyes injected with GFP packaged
with standard scAAV (p=0.0352). B: Six months post injection, this
decrement between experimental and control eyes was even more
significant (p=0.0182). C: Representative waveforms show normal
amplitude 6 months after scAAV-GFP injection but loss (D) of
PERG signal with MTS scAAV mutant ND4 injection. E: A barplot
shows an increasing reduction of the ratio of the right eye to left eye
amplitudes with 1-month (1M) and 6-month (6M) intervals post
injection  relative  to  baseline  values  (BL)  obtained  before  AAV
injections.
within the mitochondria. This is due to the partially different
genetic  codes,  where  the  TGA  codon  is  a  termination
sequence for protein synthesis in the nucleus and cytoplasm
(Figure 2E), but specifies the amino acid tryptophan within
the mitochondria (Figure 2F).
Wild-type human ND4FLAG expression in retinal ganglion
cells does not cause visual loss: Immunohistochemistry of the
retinas of eyes injected with the MTS AAV containing wild-
type human G11778G ND4 cDNA showed that in the RGC
layer (Figure 3A) where RGCs were labeled by an antibody
against  Thy1.2  (Figure  3B),  mutant  or  wild-type  human
ND4FLAG  expression  (Figure  3C)  colocalized  to  RGCs
(Figure 3D) whose axons comprised the optic nerve. Our next
step was to determine that expression of wild-type human
ND4 would not cause visual loss in mice. For this, we tested
the visual function of eyes of animals (n=6) injected with wild-
type ND4 packaged with MTS-targeted AAV. Seven weeks
after AAV injections, PERGs, a sensitive measure of RGC
and  visual  function,  showed  no  differences  in  amplitude
between eyes injected with wild-type human mitochondrial
(m)  ND4  (22.2±2.1  uV;  mean±standard  error)  relative  to
uninjected eyes (21.2±1.3, n=16; Figure 3E-F).
Mutant human G11778A ND4 causes visual loss in mice: In
contrast, starting at 1 month post injection, PERGs of the right
eyes injected with the mutant human ND4 packaged with the
MTS  scAAV  showed  a  significant  decrement  in  RGC
function (3.96±0.45 μV RMS; mean±standard error) relative
to the left eyes injected with scAAV-GFP packaged with
standard scAAV2 (5.16±0.45 μV RMS), p<0.04 (n=15 mice;
Figure 4A). Six months post injection, this decrement between
the  experimental  (4.43±0.45  μV  RMS)  and  control  eyes
(5.85±0.46 μV RMS) was maintained, p<0.02 (Figure 4B-E).
In a comparison of the 1-month PERGs and 6-month PERGs
of  the  right  eyes,  we  found  no  statistically  significant
difference (p=0.4). Similarly the left eyes injected with AAV-
GFP had no statistically significant difference in the PERGs
at 1 month relative to 6 months post injection (p=0.36). Thus,
as also seen in patients with LHON, our mice with expression
of G11778A mutant human ND4 had an initial drop in visual
function with little propensity for spontaneous recovery.
In vivo imaging of early optic disc edema and later optic nerve
head atrophy: Spectral domain optical coherence tomography
(SD-OCT)  of  right  eyes  injected  with  the  mutant  human
ND4 packaged with the MTS scAAV revealed swelling of the
optic nerve head starting at 1 month post injection (Figure 5A)
relative to the contralateral control eye injected with scAAV-
GFP (Figure 5B). One year later, optic nerve head atrophy
(Figure 5C) was apparent in the mutant ND4 injected eyes but
not  in  the  GFP  controls  (Figure  5D).  At  this  time  point,
marked focal thinning of the inner retina was also apparent
(Figure 5E) in an experimental eye but not observed in control
eyes (Figure 5F).
Postmortem  histopathology  of  retinal  ganglion  cell  loss:
Light microscopy of the eyes of mice euthanized a year post
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1675AAV injections confirmed the OCT findings. In the animal
where OCT showed marked focal thinning of the inner retina,
we found loss of the RGC and inner nuclear layers with only
the outer retina remaining (Figure 6A,B). Other animals did
not exhibit such severe inner retinal atrophy, but showed the
more characteristic loss of cells in the ganglion cell layer
Figure 5. SD-OCT imaging of optic disc edema and optic atrophy. A: Spectral domain optical coherence tomography (SD-OCT) of right eyes
injected with the mutant human ND4 packaged with the MTS scAAV revealed swelling of the optic nerve head (arrows) commencing at 1
month post injection. A focal increase in the thickness of the RGC and the inner plexiform layer (IPL) is apparent just to the right of the
swollen optic nerve head. B: The control eye injected with scAAV-GFP showed the normal anatomy of the mouse optic nerve head. C: One
year post injection, optic nerve head atrophy was apparent in the mutant ND4 injected eyes. D: The contralateral GFP injected control eyes
maintained normal optic nerve head anatomy. E: One year post injection, focal thinning with loss of the inner retina was also apparent in an
experimental eye, but this finding was not seen in any of the control eyes (F). RGC=retinal ganglion cell layer; IPL=inner plexiform layer.
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1676Figure 6. Histopathology of RGC loss. Light microscopy of the eyes of mice euthanized a year post AAV injections confirmed the OCT
findings of inner retinal loss induced by injection of the mutant ND4 MTS AAV showing marked focal thinning of the inner retina at low
(A) and higher (B) magnifications. C: While experimental eyes of other animals did not exhibit such severe inner retinal atrophy, the more
characteristic loss of cells in the ganglion cell layer was evident. Control eyes injected with scAAV-GFP showed no loss of the inner retina
layers (D and E) or cells in the RGC layer (F). ON=optic nerve, RGC=retinal ganglion cell layer, INL=inner nuclear layer, and ONL=outer
nuclear layer.
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1677Figure 7. Histopathology of optic nerve atrophy. Relative to the normal optic nerves of contralateral control eyes that received scAAV-
GFP (A, B), the hallmark optic nerve atrophy of LHON was prominent in mouse eyes injected with MTS scAAV mutant ND4 that appeared
thinner than the contralateral experimental eyes (C, D). E: A scatterplot with quantile boxes shows quantitation of the optic nerve head areas
of COX8 MTS delivered mutant (G11778A) ND4 were smaller than those of controls injected with scAAV-GFP. The lowest line of the
quantile plot represents the tenth percentile and the highest line the 90th percentile. The bottom of the quantile box represents the 25th percentile
and the top of the box the 75th percentile, with the median value in the middle of the box. Median values are slightly different from the means.
F: A scatterplot with quantile boxes shows axonal loss in MTS AAV mutant ND4 injected eyes relative to axon counts in scAAV-GFP injected
eyes. Values for nine of the mutant ND4 injected nerves were below the 25th percentile for control optic nerves injected with scAAV-GFP.
Molecular Vision 2012; 18:1668-1683 <http://www.molvis.org/molvis/v18/a172> © 2012 Molecular Vision
1678Figure 8. Ultrastructure of optic nerve axonal loss. A: One year after injection of scAAV-GFP, transmission electron micrographs disclosed
optic nerve axons (a) of various sizes enveloped by myelin sheaths. Astroglial cell processes (g) coursed between fibers of the optic nerve.
B: In this same animal, the opposite eye injected with the MTS scAAV mutant ND4 had a marked decrease in axonal density. Many empty
spaces (e) were present where axons were apparently lost in these atrophic optic nerves and degenerating axonal profiles were evident (d).
C: In a different animal, the optic nerve of the control eye injected with scAAV-GFP had normal axons (a) with the only empty space the
lumen of a blood vessel (L). D: In this animal, the opposite eye injected with the MTS scAAV mutant ND4 had a marked decrease in axonal
density. Many empty spaces (e) were present where axons were lost. a=optic nerve axon, e=empty space, g=astroglial process, d=degenerating
axon, L=lumen.
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1679(Figure  6C).  In  contrast,  eyes  injected  with  scAAV-GFP
showed no loss of the inner retina (Figure 6D,E) or cells in the
RGC layer (Figure 6F).
Postmortem  histopathology  of  optic  nerve  degeneration:
Postmortem  analysis  performed  1  year  after  intravitreal
injections confirmed that the MTS-targeted scAAV mutant
ND4 induced the hallmark optic atrophy of LHON. Relative
to the normal optic nerves of contralateral control eyes that
received  scAAV-GFP  (Figure  7A,B),  the  hallmark  optic
nerve atrophy of LHON was prominent in mouse eyes injected
with MTS scAAV mutant ND4 (Figure 7C,D). Differences in
the optic nerve areas between COX8 MTS delivered mutant
ND4 (112,469± 4,981 μm2; mean±standard error) relative to
AAV-GFP  (138,300±7,208  μm2)  were  highly  significant
(p=0.004;  Figure  7E).  Using  transmission  electron
micrographs to quantitate the number of optic nerve axons,
we found that relative to the scAAV-GFP injected eyes with
a  mean  of  260±33  (mean±standard  deviation)  axons  per
mm2, axon counts were significantly reduced in MTS AAV
mutant ND4 injected eyes with a mean of 208±24 axons per
mm2 (p=0.0004). A quantile plot shows that axon counts of
nine mutant ND4 injected optic eyes were below the 25%
quantile for the control eyes injected with AAV-GFP (Figure
7F). Thus, transmission electron microscopy confirmed that
optic atrophy was due to axonal loss.
Ultrastructural analysis of scAAV-GFP injected controls
revealed a full complement of normal axons enveloped by
myelin (Figure 8A). In sharp contrast, axonal density was
markedly reduced in the contralateral optic nerve of this same
animal, 1 year after injection of scAAV mutant ND4, (Figure
8B)  with  empty  spaces  present  where  axons  were  lost.
Ongoing axonal degeneration was still evident in some axons
with electron dense aggregations. In a different animal, the
control optic nerve injected with AAV-GFP had normal axons
and  myelin  (Figure  8C),  while  the  opposite  optic  nerve
injected with scAAV mutant ND4 showed severe axonal loss
with many empty spaces at foci where axons had been (Figure
8D). Even 1 year after the MTS scAAV mutant ND4 injection,
some  remaining  axons  were  still  in  various  stages  of
irreversible degeneration with electron dense aggregations
within the axon (Figure 9A,B). Electron lucent mitochondria
accumulated in swollen axons (Figure 9A). Fusion of two
(Figure  9B)  or  three  mitochondria  (Figure  9C)  was  also
evident  in  axons  with  otherwise  normal  appearing
neurotubules.
DISCUSSION
We have shown here that mutant G11778A ND4 DNA can be
introduced into the murine mitochondria of the inner retina,
where  the  expression  of  the  DNA  leads  to  significant
mitochondrial perturbations causing loss of visual function,
culminating  in  retinal  ganglion  cell  and  optic  nerve
degeneration that are the hallmarks of human LHON [14,15].
Ocular specimens of autopsied patients with LHON show loss
Figure 9. Mitochondria accumulate and fuse. A: Optic nerves from
mutant ND4 MTS AAV injected eyes exhibited some large-caliber
axons (a) with the accumulation of mitochondria (arrow) of varying
diameters.  Electron-dense  aggregations  indicative  of  irreversible
axonal degeneration were also evident (double arrows). B: In some
swollen  axons,  two  mitochondria  were  seen  fusing  (arrows).
Irreversible axonal degeneration with intra-axonal electron dense
aggregations was evident in other axons (d). C: In another axon, three
mitochondria (arrows) appeared to fuse.
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accumulations of abnormal mitochondria also seen in our
animal model system [15]. As human and mouse ND4 DNA
sequences are approximately three-quarters homologous, we
excluded a potential adverse consequence of wild-type human
ND4 expression in the murine retina. Using the pattern PERG,
a sensitive measure of RGC function, we found no significant
differences  in  amplitude  relative  to  the  eyes  of  normal
animals. Thus, unlike the mutant ND4 allele, rodent visual
function  did  not  appear  to  be  altered  by  the  import  and
expression of the wild-type human ND4 allele [12]. Nor did
we observe retinal ganglion cell loss following intravitreal
injection of scAAV-WT-ND4.
Although a natural DNA mitochondrial import had been
reported in isolated rat liver mitochondria [16] and in plants
[17], exogenous DNA cannot be transfected into mitochondria
with conventional techniques [18,19].
Our work shows that fusing an AAV capsid protein with
a  mitochondrial  targeting  sequence  makes  an  efficient
delivery  system  for  importing  a  relevant  gene  into  the
mitochondria of living cells in the mouse visual system where
it induced the anticipated characteristic phenotype. Studies by
others have conjugated an MTS to exogenous proteins and
small  linear  DNA,  which  enhanced  their  delivery  to
mitochondria  [13,20],  but  that  strategy  failed  in  cases  of
macromolecules  and  hydrophobic  molecules  including
mtDNA  and  mitochondrial  proteins  [21].  Liposome-based
carriers can import hybrid molecules into mitochondria of
whole cells, but this approach has low efficiency and high
cytotoxicity [18,22,23]. Mutated mtDNA can potentially be
removed  from  the  germ  line  by  transfer  of  the  spindle-
chromosomal  complex  from  one  egg  to  another  that  is
enucleated and depleted of its mitochondria [24]. A major
limitation of this successful approach is that it cannot be used
after birth, and the technology has not yet been demonstrated
to actually exert a mitochondrial phenotype. In contrast, our
MTS AAV approach resulted in expression of mutant human
ND4 in mitochondria where it induced visual loss and optic
atrophy, thus suggesting that our novel technology may also
be  useful  long  after  birth  for  inserting  DNA  into  the
mitochondria of live animals.
Animal models of human mitochondrial diseases could
be the substrate for testing therapies for human mitochondrial
disorders, but these models are scarce, as discussed in a recent
review  article  [25].  These  models  include  mutations
introduced  into  nuclear  genes  encoding  mitochondrial
proteins  to  induce  defective  oxidative  phosphorylation  by
complex I deficiency [26,27]. A limitation of these mouse
model systems is that the defects are rapidly fatal. We took a
similar  approach  by  reducing  expression  of  the  NDUFAI
subunit of complex I [7]. With expression limited to the visual
system, this approach induced optic nerve degeneration but
was  not  fatal.  That  study  emphasized  the  importance  of
complex I to an organ system, the optic nerve that has a high
density of mitochondria.
Since approximately 85% of mitochondrial proteins are
encoded  in  the  nucleus,  synthesized  on  cytoplasmic
ribosomes, and then imported into the mitochondria under the
direction  of  a  mitochondrial  targeting  sequence,  we  used
“allotopic” expression to import a synthetic ND4 recoded in
the nuclear genetic code that induced a phenotype resembling
human  LHON  in  mice  [8].  Another  group  independently
suppressed visual loss and RGC demise by adding back in the
allotopically  expressed  wild-type  ND4  allele  [28].  The
allotopic expression technique developed almost 10 years ago
is only now under investigation for human LHON clinical
trials  [12].  Still,  a  limitation  of  the  allotopic  expression
technology is that it appears to be highly dependent on the
MTS,  the  recoded  mitochondrial  gene,  and  the  appended
epitope  tag  used  for  immunodetection  [1].  Moreover,
allotopic  expression  is  useful  only  for  expressing  the  13
proteins encoded by mitochondrial DNA. Our technology for
delivering  DNA  to  mitochondria  is  useful  for  generating
relevant animal models for these disorders as well as other
disorders such as mitochondrial encephalomyopathy, lactic
acidosis, and stroke-like episodes or myoclonic epilepsy and
ragged red fibers caused by mutations in tRNAs encoding
mitochondrial genes or others disorders such as Kearns-Sayre
syndrome and chronic progressive external ophthalmoplegia
caused by large deletions in the mitochondrial genome [29].
Using an MTS to direct a virus to deliver a mitochondrial
gene to the organelle may be more versatile. Rather than
introducing a mutant mitochondrial gene, MTS AAV may
also be useful for introducing the wild-type allele into patients
with mutated mitochondrial DNA. We anticipate that DNA
encoding tRNAs or deletions in the mitochondrial genome
may also be shuttled into the mitochondria with MTS AAV
technology. As shown here, the technology can be extremely
useful for creating a bona fide animal model of LHON with
the desired phenotype in the target organ system. Relevant
animal model systems with mutated mitochondrial DNA are
highly relevant for testing potential therapies for the many
diseases caused by mutated mitochondrial DNA. We look
forward to providing this delivery system to other laboratories
for introducing other mutant mitochondrial genes by injecting
MTS AAV into other organ systems such as the brain, heart,
or skeletal muscle of animals and eventually for the benefit of
the multitude of patients afflicted by disorders caused by
mutated mitochondrial DNA for whom there is currently no
effective remedy.
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